Apatinib Mesylate

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Subjects With Impaired Renal Function and Healthy Subjects

Conditions

Subjects With Impaired Renal Function and Healthy Subjects

Trial Timeline

Jun 5, 2020 → Apr 30, 2021

NCT ID

NCT04414852

About Apatinib Mesylate

Apatinib Mesylate is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Subjects With Impaired Renal Function and Healthy Subjects. The current trial status is unknown. This product is registered under clinical trial identifier NCT04414852. Target conditions include Subjects With Impaired Renal Function and Healthy Subjects.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04414852	Phase 1	UNKNOWN	Jun 5, 2020	Apr 30, 2021	Subjects With Impaired Renal Function and Healthy Subjects
NCT04341090	Phase 1	Completed	May 13, 2020	Jul 6, 2020	Healthy Subjects

Competing Products

20 competing products in Subjects With Impaired Renal Function and Healthy Subjects

See all competitors

Product	Company	Stage	Hype Score
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Alkem Laboratories	Phase 1	33
Moxifloxacin + Placebo + Lanifibranor + Placebo	Inventiva	Phase 1	28
Pegilodecakin	Eli Lilly	Phase 1	33
CT-P41 + EU-approved Prolia	Celltrion	Phase 1	33
CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx	Celltrion	Phase 1	33
CT-P52	Celltrion	Phase 1	33
CT-P47 + EU-approved RoActemra,	Celltrion	Phase 1	33
CT-P47 + CT-P47	Celltrion	Phase 1	33
CT-P43 + EU-approved Stelara + US-licensed Stelara	Celltrion	Phase 1	33
CT-P43 + CT-P43	Celltrion	Phase 1	33
YHP2406 + YHR2501	Yuhan	Phase 1	33
YH35324 + Placebo + Omalizumab	Yuhan	Phase 1	33
YHP2511 + YHP2511A	Yuhan	Phase 1	33
YH35324 + Placebo + Omalizumab	Yuhan	Phase 1	33
Bempedoic acid + Ezetimibe + Atorvastatin	Daiichi Sankyo	Phase 1	33
Quizartinib dihydrochloride + 14C-Quizartinib solution for infusion	Daiichi Sankyo	Phase 1	33
Bempedoic acid + Ezetimibe + Rosuvastatin	Daiichi Sankyo	Phase 1	33
Quizartinib + Rufinamide	Daiichi Sankyo	Phase 1	33
Quizartinib	Daiichi Sankyo	Phase 1	33
Efavirenz + Quizartinib	Daiichi Sankyo	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved